245 related articles for article (PubMed ID: 15123247)
21. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design.
Kontopidis G; McInnes C; Pandalaneni SR; McNae I; Gibson D; Mezna M; Thomas M; Wood G; Wang S; Walkinshaw MD; Fischer PM
Chem Biol; 2006 Feb; 13(2):201-11. PubMed ID: 16492568
[TBL] [Abstract][Full Text] [Related]
22. Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors.
Rossi KA; Markwalder JA; Seitz SP; Chang CH; Cox S; Boisclair MD; Brizuela L; Brenner SL; Stouten PF
J Comput Aided Mol Des; 2005 Feb; 19(2):111-22. PubMed ID: 16075305
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
Ibrahim DA; Ismail NS
Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors.
McIntyre NA; McInnes C; Griffiths G; Barnett AL; Kontopidis G; Slawin AM; Jackson W; Thomas M; Zheleva DI; Wang S; Blake DG; Westwood NJ; Fischer PM
J Med Chem; 2010 Mar; 53(5):2136-45. PubMed ID: 20146435
[TBL] [Abstract][Full Text] [Related]
25. Pyrimidine-based inhibitors of CaMKIIdelta.
Mavunkel B; Xu YJ; Goyal B; Lim D; Lu Q; Chen Z; Wang DX; Higaki J; Chakraborty I; Liclican A; Sideris S; Laney M; Delling U; Catalano R; Higgins LS; Wang H; Wang J; Feng Y; Dugar S; Levy DE
Bioorg Med Chem Lett; 2008 Apr; 18(7):2404-8. PubMed ID: 18334293
[TBL] [Abstract][Full Text] [Related]
26. Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein.
Ikuta M; Kamata K; Fukasawa K; Honma T; Machida T; Hirai H; Suzuki-Takahashi I; Hayama T; Nishimura S
J Biol Chem; 2001 Jul; 276(29):27548-54. PubMed ID: 11335721
[TBL] [Abstract][Full Text] [Related]
27. Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.
Jaramillo C; de Diego JE; Hamdouchi C; Collins E; Keyser H; Sánchez-Martínez C; del Prado M; Norman B; Brooks HB; Watkins SA; Spencer CD; Dempsey JA; Anderson BD; Campbell RM; Leggett T; Patel B; Schultz RM; Espinosa J; Vieth M; Zhang F; Timm DE
Bioorg Med Chem Lett; 2004 Dec; 14(24):6095-9. PubMed ID: 15546737
[TBL] [Abstract][Full Text] [Related]
28. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.
Dessalew N; Bharatam PV
Eur J Med Chem; 2007 Jul; 42(7):1014-27. PubMed ID: 17335939
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin.
Aubry C; Wilson AJ; Jenkins PR; Mahale S; Chaudhuri B; Maréchal JD; Sutcliffe MJ
Org Biomol Chem; 2006 Mar; 4(5):787-801. PubMed ID: 16493461
[TBL] [Abstract][Full Text] [Related]
30. Protein kinase inhibitors: insights into drug design from structure.
Noble ME; Endicott JA; Johnson LN
Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
[TBL] [Abstract][Full Text] [Related]
31. Cyclin-dependent kinase inhibitors.
Fischer PM; Endicott J; Meijer L
Prog Cell Cycle Res; 2003; 5():235-48. PubMed ID: 14593718
[TBL] [Abstract][Full Text] [Related]
32. Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition.
Gussio R; Zaharevitz DW; McGrath CF; Pattabiraman N; Kellogg GE; Schultz C; Link A; Kunick C; Leost M; Meijer L; Sausville EA
Anticancer Drug Des; 2000 Feb; 15(1):53-66. PubMed ID: 10888036
[TBL] [Abstract][Full Text] [Related]
33. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol.
de Azevedo WF; Canduri F; da Silveira NJ
Biochem Biophys Res Commun; 2002 Apr; 293(1):566-71. PubMed ID: 12054639
[TBL] [Abstract][Full Text] [Related]
34. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
Krystof V; Cankar P; Frysová I; Slouka J; Kontopidis G; Dzubák P; Hajdúch M; Srovnal J; de Azevedo WF; Orság M; Paprskárová M; Rolcík J; Látr A; Fischer PM; Strnad M
J Med Chem; 2006 Nov; 49(22):6500-9. PubMed ID: 17064068
[TBL] [Abstract][Full Text] [Related]
35. 4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4).
Tsou HR; Otteng M; Tran T; Floyd MB; Reich M; Birnberg G; Kutterer K; Ayral-Kaloustian S; Ravi M; Nilakantan R; Grillo M; McGinnis JP; Rabindran SK
J Med Chem; 2008 Jun; 51(12):3507-25. PubMed ID: 18494457
[TBL] [Abstract][Full Text] [Related]
36. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design.
Kontopidis G; Andrews MJ; McInnes C; Plater A; Innes L; Renachowski S; Cowan A; Fischer PM
ChemMedChem; 2009 Jul; 4(7):1120-8. PubMed ID: 19472269
[TBL] [Abstract][Full Text] [Related]
37. 2-Aminoquinazoline inhibitors of cyclin-dependent kinases.
Bathini Y; Singh I; Harvey PJ; Keller PR; Singh R; Micetich RG; Fry DW; Dobrusin EM; Toogood PL
Bioorg Med Chem Lett; 2005 Sep; 15(17):3881-5. PubMed ID: 15993068
[TBL] [Abstract][Full Text] [Related]
38. Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation.
Anderson M; Beattie JF; Breault GA; Breed J; Byth KF; Culshaw JD; Ellston RP; Green S; Minshull CA; Norman RA; Pauptit RA; Stanway J; Thomas AP; Jewsbury PJ
Bioorg Med Chem Lett; 2003 Sep; 13(18):3021-6. PubMed ID: 12941325
[TBL] [Abstract][Full Text] [Related]
39. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
Singh SK; Dessalew N; Bharatam PV
Eur J Med Chem; 2006 Nov; 41(11):1310-9. PubMed ID: 16890327
[TBL] [Abstract][Full Text] [Related]
40. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: synthesis, biological evaluation, and structure-activity relationships.
Horiuchi T; Chiba J; Uoto K; Soga T
Bioorg Med Chem Lett; 2009 Jan; 19(2):305-8. PubMed ID: 19091560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]